GSK Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GSK Bundle
What is included in the product
Detailed Word Document
Tailored analysis for GSK's product portfolio, including strategic implications.
Customizable Excel Spreadsheet
Visually prioritizes business units to guide resource allocation and strategic decisions.
Preview = Final Product
GSK BCG Matrix
The displayed BCG Matrix preview is identical to the full document you'll receive upon purchase. This means no changes, no hidden content, and ready-to-go strategic insights for your use immediately.
BCG Matrix Template
Actionable Strategy Starts Here
Uncover the strategic landscape of [Company Name] with the BCG Matrix, a key tool for understanding product portfolios. Stars, Cash Cows, Dogs, Question Marks – each quadrant reveals crucial market dynamics. This preview provides a glimpse into their product positions and potential growth. Get the full BCG Matrix report to uncover detailed quadrant placements, data-backed recommendations, and a roadmap to smart investment and product decisions.
Stars
HIV Portfolio (Cabenuva, Apretude, Dovato)
GSK's HIV portfolio, a "Star" in its BCG matrix, shows substantial growth. The HIV franchise brought in $7.1 billion in 2024, marking a 13% year-over-year increase. This growth is fueled by long-acting injectables like Cabenuva, which exceeded $1.01 billion in sales, and oral treatments like Dovato. A 2% market share increase, pricing, and channel mix positively impacted results.
Oncology Portfolio (Jemperli, Ojjaara)
GSK's oncology portfolio, including Jemperli and Ojjaara, is a significant growth driver. Oncology sales surged 98% in 2024. Jemperli, used for endometrial cancer, and Ojjaara, for myelofibrosis, are key products. This growth highlights GSK's focus on oncology.
Trelegy Ellipta (COPD and Asthma)
Trelegy Ellipta, used for COPD and asthma, saw a 27% sales increase in 2024. This growth highlights global demand for triple therapy inhalers. As the most prescribed SITT globally, Trelegy significantly boosts GSK's General Medicines. Its success is a key factor in GSK's overall performance.
Blenrep (belantamab mafodotin) - Multiple Myeloma
Blenrep, an antibody-drug conjugate, is poised for a market comeback in multiple myeloma treatment following positive Phase 3 trial results. GSK anticipates peak sales exceeding 3 billion pounds sterling, fueled by its efficacy against Johnson & Johnson's Darzalex. UK MHRA has approved Blenrep combinations, with submissions in 14 other markets. FDA approval is anticipated by July 2025.
- Blenrep's potential peak sales: Over 3 billion pounds sterling.
- Regulatory status: Approved in the UK, submissions in 14 other markets.
- FDA approval target: July 2025.
- Treatment focus: Multiple myeloma.
Late-Stage Pipeline Assets
GSK's late-stage pipeline is a significant strength, featuring 71 specialty medicines and vaccines in clinical development. Nineteen of these assets are in Phase III or registration, showcasing a deep commitment to innovation. Key therapeutic areas include respiratory, immunology, oncology, HIV, and infectious diseases. With five major product approvals expected in 2025, such as Blenrep and depemokimab, GSK is positioned for growth.
- 71 specialty medicines and vaccines in clinical development.
- 19 assets in Phase III or registration.
- Focus on respiratory, immunology, oncology, HIV, and infectious diseases.
- Anticipated five major new product approvals in 2025.
GSK's Stellar Performers: HIV, Oncology, and Trelegy Shine!
GSK's "Stars" include the HIV portfolio, oncology, and Trelegy. HIV sales were $7.1B in 2024, up 13%. Oncology sales jumped 98% in 2024. Trelegy's sales grew 27%, demonstrating strong performance.
| Star Product | 2024 Sales (USD) | YOY Growth |
|---|---|---|
| HIV Franchise | $7.1B | 13% |
| Oncology | Significant Increase | 98% |
| Trelegy Ellipta | Not Specified | 27% |
Cash Cows
Shingrix (Shingles Vaccine)
Shingrix, GSK's shingles vaccine, is a cash cow. In 2024, its sales grew by a mere 1%. This was due to challenges in reaching unvaccinated people and shifts in vaccination priorities. Despite the slowdown, Shingrix still generates substantial revenue for GSK.
Established Vaccines (Meningitis, Hepatitis)
GSK's established vaccines, like those for meningitis and hepatitis, remain crucial revenue drivers. Bexsero, a meningitis vaccine, saw double-digit growth in 2024, with sales surpassing £1 billion. This boost stems from favorable pricing, increased US CDC purchases, and global recommendations. These factors solidify the vaccines' cash cow status.
Nucala (Respiratory Eosinophil-Driven Diseases)
Nucala, addressing respiratory eosinophil-driven diseases, maintains robust performance. It's the initial treatment approved in the US and Europe for four IL-5 mediated conditions. This drives patient demand. In 2024, Nucala's sales are expected to be significant across key markets.
Benlysta (Lupus and Lupus Nephritis)
Benlysta, a biologic treatment for lupus and lupus nephritis, is a key asset for GSK. Approved for both Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN), it holds a unique market position. It's approved for adults and pediatrics in the US, Europe, and other regions. This broad approval base supports its continued financial performance.
- 2023 sales reached £489 million, showing strong growth.
- Benlysta is the only biologic approved for both SLE and LN.
- It's approved in over 70 countries.
- Pediatric approval enhances market reach.
Augmentin and Ceftum
Augmentin and Ceftum, key products in GSK's general medicines, have shown share growth, solidifying their market presence. These are reliable revenue generators, particularly in significant markets. Their established status ensures consistent financial contributions. These brands are crucial for GSK's financial stability.
- Augmentin and Ceftum are classified as Cash Cows in GSK's BCG Matrix.
- They generate substantial, consistent cash flow.
- These drugs have a strong market position with increasing market shares.
- They are well-established in key markets.
Cash Cows: Steady Revenue Streams
GSK's cash cows are robust revenue generators.
These established products, like vaccines and certain medicines, provide consistent financial contributions. Augmentin and Ceftum have a strong market presence, with increasing market shares.
| Product | Category | Sales Performance (2024 Est.) |
|---|---|---|
| Shingrix | Vaccine | 1% Growth |
| Bexsero | Vaccine | Double-digit growth, £1B+ sales |
| Augmentin/Ceftum | General Medicine | Share Growth |
Dogs
Fluarix/FluLaval (Influenza Vaccines)
GSK's influenza vaccines, like Fluarix/FluLaval, face sales declines. These declines stem from tough competition and reduced demand, especially in the US market. In 2023, GSK's vaccine sales were affected by these market dynamics. Specifically, the influenza vaccine market is very competitive. Overall, GSK's financial results reflect these market pressures.
Older General Medicine Products (Advair/Flovent)
Advair and Flovent, older respiratory drugs from GSK, have seen sales decline due to generic competition. These drugs operate in mature markets, limiting growth opportunities within GSK's portfolio. In 2023, Advair's sales decreased, reflecting these challenges. The products' reduced profitability impacts GSK's overall financial performance.
Blenrep (as monotherapy before relaunch)
Blenrep, a withdrawn monotherapy, now sits as a 'dog' in GSK's BCG Matrix. It was pulled from the US and EU markets after a failed Phase 3 trial. Its future hinges on combination therapies, not its original form. In 2023, GSK's total revenue was £28.5 billion, but Blenrep's contribution was minimal.
COVID-19 related products
GSK's COVID-19 related products are now considered Dogs in its BCG matrix. The company doesn't expect further sales or profit from this sector. This shift negatively affected 2024's growth, with sales and core operating profit down. The impact was significant compared to 2023.
- Sales growth was negatively impacted by one percentage point.
- Core operating profit was adversely affected by two percentage points.
- GSK no longer anticipates revenue from COVID-19 products.
- The shift reflects a strategic pivot away from pandemic-related offerings.
Certain divested brands
In 2024, established vaccine sales included approximately £130 million from non-repeating contracted sales, encompassing divested brands. These divested brands, no longer part of GSK's portfolio, will not contribute to future revenue generation. This strategic move is part of GSK's efforts to streamline its business. The focus is now on core growth areas.
- £130 million from divested brands in 2024.
- These brands are no longer part of GSK's future revenue.
- Strategic move to focus on core growth areas.
GSK's "Dogs": Products with Low Growth and Market Share
GSK's "Dogs" are products with low market share and growth. Blenrep, Advair, Flovent and COVID-19 products are examples. They contribute minimally to revenue. They are a drag on profitability.
| Product Category | Status | Impact |
|---|---|---|
| Blenrep | Withdrawn | Minimal revenue |
| COVID-19 Products | Declining | No future revenue |
| Advair/Flovent | Declining | Generic competition |
| Divested Brands | Sold | No future revenue |
Question Marks
Arexvy (RSV Vaccine)
Arexvy, GSK's RSV vaccine, saw a 51% sales decrease in 2024 due to the CDC's age recommendations. Despite its US market leadership, reduced demand creates uncertainty. GSK anticipates potential future cohort expansion and revaccination opportunities. In 2024, Arexvy generated £789 million in sales.
Depemokimab (Severe Asthma)
Depemokimab, a late-stage asset for severe asthma and CRSwNP, is a key part of GSK's pipeline. Approval and launch in 2025 could boost GSK's respiratory portfolio, which generated £5.8 billion in sales in 2023. Success hinges on positive trial results and regulatory approvals, with peak sales estimates varying significantly.
Camlipixant (Refractory Chronic Cough)
Camlipixant, a promising asset in GSK's pipeline, showed positive Phase 3 results for refractory chronic cough. Regulatory approval is anticipated in 2025, targeting an unmet need. However, market uptake and competition will determine its commercial success. The chronic cough market was valued at $2.5 billion in 2024.
Tebipenem (Complicated Urinary Tract Infections)
Tebipenem, with positive Phase 3 results for complicated urinary tract infections, is a potential 2025 approval. This could offer a new treatment option in a market where the global antibiotics market was valued at $44.7 billion in 2023. Market performance depends on efficacy, safety, and competition.
- 2023 Global antibiotics market value: $44.7 billion.
- Phase 3 trial success supports potential approval.
- Efficacy, safety, and competition are key factors.
- 2025 approval could introduce a new option.
New Business Development Deals (Aiolos Bio, IDRx)
GSK's strategic moves in new business development, such as acquiring Aiolos Bio for asthma and IDRx for gastrointestinal cancers, highlight potential growth avenues. These acquisitions are crucial for expanding GSK's product portfolio and market presence. The success of these deals hinges on successful clinical development and commercialization strategies.
- Aiolos Bio focuses on developing treatments for respiratory diseases, and IDRx specializes in gastrointestinal cancers.
- These acquisitions align with GSK's strategy to strengthen its pipeline in key therapeutic areas.
- Successful commercialization will significantly impact GSK's revenue and market share.
- The deals represent a long-term investment in innovation and growth within the pharmaceutical sector.
Respiratory Portfolio: £5.8B in 2023, Future Uncertain
Arexvy, despite leading the US market, faces uncertainty due to reduced demand, generating £789 million in 2024. Depemokimab's 2025 launch could enhance the £5.8 billion 2023 respiratory portfolio. Camlipixant and Tebipenem represent opportunities amid competitive markets.
| Asset | Category | 2024 Sales/Market Value |
|---|---|---|
| Arexvy | Question Mark | £789 million |
| Depemokimab | Question Mark | Anticipated Launch in 2025 |
| Camlipixant | Question Mark | $2.5 billion (Chronic Cough Mkt) |
| Tebipenem | Question Mark | $44.7 billion (Antibiotics Mkt - 2023) |
BCG Matrix Data Sources
The GSK BCG Matrix is data-driven, using sales figures, market growth data, industry reports, and expert opinions for analysis.
